PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

Metastatic prostate cancer (PCa) has high mortality and a poor 5-year survival rate primarily due to the lack of effective treatments. Bone is the primary site of PCa metastasis in humans and the development of reliable therapeutic options for bone metastatic PCa will make a huge impact in reducing...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biochem Pharmacol
Asıl Yazarlar: Verma, Arti, Artham, Sandeep, Alwhaibi, Abdulrahman, Adil, Mir S., Cummings, Brian S., Somanath, Payaningal R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414983/
https://ncbi.nlm.nih.gov/pubmed/32240651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.113943
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller